Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-88545223 dose-ranging study in active psoriatic arthritis
2025-523141-10-00Phase 2Suspended
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in psoriatic arthritis (PsA) comparing JNJ-88545223 dose arm(s) with Placebo (2 arms). Primary endpoint: ACR50 response at Week 16. Started Mar 2026; status: suspended.
02
Drugs
JNJ-88545223
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2025-523141-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523141-10-00.